Pascal Vranckx1, Enrico Frigoli2, Martina Rothenbühler3, Francesco Tomassini4, Stefano Garducci5, Giuseppe Andò6, Andrea Picchi7, Paolo Sganzerla8, Anita Paggi9, Fabrizio Ugo10, Arturo Ausiello11, Gennaro Sardella12, Nicoletta Franco13, Marco Nazzaro14, Nicoletta de Cesare15, Paolo Tosi16, Camillo Falcone17, Carlo Vigna18, Pietro Mazzarotto19, Emilio Di Lorenzo20, Claudio Moretti21, Gianluca Campo22, Carlo Penzo23, Giampaolo Pasquetto24, Dik Heg3, Peter Jüni25, Stephan Windecker26, Marco Valgimigli26. 1. Department of Cardiology and Critical Care Medicine, Hartcentrum Hasselt, Jessa Ziekenhuis, Stadsomvaart 11, 3500 Hasselt, Belgium. 2. EUSTRATEGY Association, Forli' (FC), Italy. 3. Clinical Trials Unit and Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, 3012 Bern, Switzerland. 4. Cardiology Unit, Ospedali Riuniti di Rivoli, ASL Torino 3, Str. del Barocchio, 25, 10095 Turin, Italy. 5. Ospedale Civile di Vimercate (MB), Via Santi Cosma e Damiano, 10, 20871 Vimercate MB, Italy. 6. Azienda Ospedaliera Universitaria Policlinico "Gaetano Martino", University of Messina, Via Consolare Valeria, 1, 98125 Messina ME , Italy. 7. UO Cardiologia, ASL 9 Grosseto, Via Senese - Grosseto; 58100 Grosseto, Italy. 8. AO Ospedale Treviglio-Caravaggio, Piazzale Ospedale, 1, 24047 Treviglio BG, Italy. 9. Azienda Ospedaliera Sant'Anna, Via Ravona, 20, 22020 San fermo della battaglia Como, Italy. 10. San Giovanni Bosco Hospital, Piazza del Donatore di Sangue, 3, 10154 Turin, Italy. 11. Casa di Cura Villa Verde, Via Golfo di Taranto, 22, 74121 Taranto, Italy. 12. Policlinico Umberto I, "Sapienza" University of Rome, Piazzale Aldo Moro, 5, 00185 Rome, Italy. 13. Cardiovascular Department, Infermi Hospital, Viale Luigi Settembrini, 2, 47900 Rimini, Italy. 14. San Camillo-Forlanini, Circonvallazione Gianicolense, 87, 00152 Rome, Italy. 15. Policlinico San Marco, Corso Europa, 7, 24040 Zingonia, Osio Sotto BG, Italy. 16. Mater Salutis Hospita, Via Carlo Gianella, 37045 Legnago VR, Italy. 17. Osepdale Sacra Famiglia Fatebenefratelli, Erba, Fatebenefratelli, 22036 Como CO, Italy. 18. Casa Sollievo della Sofferenza, San Giovanni Rotodondo Foggia, Viale Cappuccini, 1, 71013 San Giovanni Rotondo FG, Italy. 19. Ospedale di Lodi, Strada Provinciale 19, 1, 26866 Sant'Angelo Lodigiano LO, Italy. 20. Ospedale San Giuseppe Moscati, Contrada Amoretta, 83100 Avellino AV, Italy. 21. A.O.U. San Giovanni Battista Molinette di Torino, Corso Bramante, 88, 10126 Turin Italy. 22. Azienda Ospedaliera Universitaria di Ferrara, Via Aldo Moro, 8, 44124 Ferrara FE, Italy. 23. Ospedale Civile di Mirano, Via Zinelli, 30035 Mirano Venezia VE, Italy. 24. Ospedali Riuniti Padova Sud, SR10var, 35043 Monselice PD. 25. Applied Health Research Centre (AHRC), Li Ka Shing Knowledge Institute of St. Michael's Hospital, and Department of Medicine, University of Toronto, Bond Street 30, ON M5B1W8, Toronto, Canada. 26. Swiss Cardiovascular Center Bern, Bern University Hospital Freiburgstrasse 8, 3010 Bern, Switzerland (M.V.; S.W.) and Thoraxcenter, Erasmus Medical Center, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.
Abstract
Aims: To assess whether radial compared with femoral access is associated with consistent outcomes in patients with ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation acute coronary syndrome (NSTE-ACS). Methods and results: In the Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX (MATRIX) programme patients were randomized to radial or femoral access, stratified by STEMI (2001 radial, 2009 femoral) and NSTE-ACS (2196 radial, 2198 femoral). The 30-day co-primary outcomes were major adverse cardiovascular events (MACE), defined as death, myocardial infarction, or stroke, and net adverse clinical events (NACE), defined as MACE or major bleeding In the overall study population, radial access reduced the NACE but not MACE endpoint at the prespecified 0.025 alpha. MACE occurred in 121 (6.1%) STEMI patients with radial access vs. 126 (6.3%) patients with femoral access [rate ratio (RR) = 0.96, 95% CI = 0.75-1.24; P = 0.76] and in 248 (11.3%) NSTE-ACS patients with radial access vs. 303 (13.9%) with femoral access (RR = 0.80, 95% CI = 0.67-0.96; P = 0.016) (Pint = 0.25). NACE occurred in 142 (7.2%) STEMI patients with radial access and in 165 (8.3%) patients with femoral access (RR = 0.86, 95% CI = 0.68-1.08; P = 0.18) and in 268 (12.2%) NSTE-ACS patients with radial access compared with 321 (14.7%) with femoral access (RR = 0.82, 95% CI = 0.69-0.97; P = 0.023) (Pint = 0.76). All-cause mortality and access site-actionable bleeding favoured radial access irrespective of ACS type (Pint = 0.11 and Pint = 0.36, respectively). Conclusion: Radial as compared with femoral access provided consistent benefit across the whole spectrum of patients with ACS, without evidence that type of presenting syndrome affected the results of the random access allocation. Published on behalf of the European Society of Cardiology. All rights reserved.
RCT Entities:
Aims: To assess whether radial compared with femoral access is associated with consistent outcomes in patients with ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation acute coronary syndrome (NSTE-ACS). Methods and results: In the Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX (MATRIX) programme patients were randomized to radial or femoral access, stratified by STEMI (2001 radial, 2009 femoral) and NSTE-ACS (2196 radial, 2198 femoral). The 30-day co-primary outcomes were major adverse cardiovascular events (MACE), defined as death, myocardial infarction, or stroke, and net adverse clinical events (NACE), defined as MACE or major bleeding In the overall study population, radial access reduced the NACE but not MACE endpoint at the prespecified 0.025 alpha. MACE occurred in 121 (6.1%) STEMI patients with radial access vs. 126 (6.3%) patients with femoral access [rate ratio (RR) = 0.96, 95% CI = 0.75-1.24; P = 0.76] and in 248 (11.3%) NSTE-ACSpatients with radial access vs. 303 (13.9%) with femoral access (RR = 0.80, 95% CI = 0.67-0.96; P = 0.016) (Pint = 0.25). NACE occurred in 142 (7.2%) STEMI patients with radial access and in 165 (8.3%) patients with femoral access (RR = 0.86, 95% CI = 0.68-1.08; P = 0.18) and in 268 (12.2%) NSTE-ACSpatients with radial access compared with 321 (14.7%) with femoral access (RR = 0.82, 95% CI = 0.69-0.97; P = 0.023) (Pint = 0.76). All-cause mortality and access site-actionable bleeding favoured radial access irrespective of ACS type (Pint = 0.11 and Pint = 0.36, respectively). Conclusion: Radial as compared with femoral access provided consistent benefit across the whole spectrum of patients with ACS, without evidence that type of presenting syndrome affected the results of the random access allocation. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Matthias Hasun; Jakob Dörler; Hannes F Alber; Axel Bauer; Rudolf Berger; Günter Christ; Matthias Frick; Uta C Hoppe; Kurt Huber; Gudrun Lamm; Elisabeth Laßnig; Dirk von Lewinski; Anna Rab; Franz X Roithinger; Herwig Schuchlenz; Peter Siostrzonek; Johann Sipötz; Thomas Stefenelli; Clemens Steinwender; Michael Edlinger; Franz Weidinger Journal: Cardiovasc Diagn Ther Date: 2021-06
Authors: Ahmed A Kolkailah; Rabah S Alreshq; Ahmed M Muhammed; Mohamed E Zahran; Marwah Anas El-Wegoud; Ashraf F Nabhan Journal: Cochrane Database Syst Rev Date: 2018-04-18
Authors: Shashank Murali; Sara Vogrin; Samer Noaman; Diem T Dinh; Angela L Brennan; Jeffrey Lefkovits; Christopher M Reid; Nicholas Cox; William Chan Journal: J Clin Med Date: 2020-05-11 Impact factor: 4.241
Authors: Florian Prüller; Lukasz Bis; Oliver Leopold Milke; Friedrich Fruhwald; Sascha Pätzold; Siegfried Altmanninger-Sock; Jolanta Siller-Matula; Friederike von Lewinski; Klemens Ablasser; Michael Sacherer; Dirk von Lewinski Journal: J Clin Med Date: 2018-11-15 Impact factor: 4.241